风湿病治疗药物的药物基因组学研究及进展  

Progress of Pharmacogenomics on Rheumatic Drugs Treatment

作　　者：童强[1] 徐霞[1] 蔡青[1] 

机构地区：[1]第二军医大学附属长海医院风湿免疫科,上海200433

出　　处：《现代生物医学进展》2012年第1期198-200,194,共4页Progress in Modern Biomedicine

基　　金：上海市科委基础研究重点项目(08JC1406300)

摘　　要：风湿病的传统治疗以激素和甲氨蝶呤为代表的改善病情药物为主,随着分子水平研究的深入,以肿瘤坏死因子α阻断剂为代表的多种靶向生物制剂进入临床。药物的选择性治疗必须依靠基因组及药物遗传学的研究,对不同患者疗效及药物毒副反应作个体化的分析,从而正确的选择药物。本文就风湿病的传统的甲氨蝶呤和TNF-α阻断剂在药物基因组学预测药物的疗效及副作用等进行综述。Methotrexate and glucocorticoid as the representative of improving condition-based drugs used in traditional treatment of rheumatism,with study of the molecular level depth,the tumor necrosis factor α blockers as the representative of a variety of targeted biological agents come into the clinic.The selective drug treatment must rely on pharmacogenetics,analysising different patients out-comes and drug toxicity for individual to choose the right medicine.We reviewed the traditional methotrexate and TNF-α blockers in pharmacogenomics predict drug efficacy and adverse effects in rheumatism.

关 键 词：风湿病 单核基因多态性 甲氨蝶呤 TNF-α阻断剂 

分 类 号：R593[医药卫生—内科学]